Carl Zeiss Meditec Stock

Carl Zeiss Meditec AG operates as a medical technology company worldwide. The company has subsidiaries in Germany, France, Spain, the U.S.A., and Japan.

The company operates in two main areas, such as Ophthalmology and Microsurgery. Business operations are summarized according to similar areas of application and customer groups in both the Ophthalmic Devices (OPT) SBU (strategic business unit) and the Microsurgery (MCS) SBU.

Ophthalmic Devices

In ophthalmology, a distinction is made between conditions, such as vision defects (refraction), cataracts, glaucoma and other retinal disorders, the incidence of which particularly increases with age and could become chronic in various cases.

In the Ophthalmic Devices SBU, the company mainly offers a portfolio of products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. The company's intention is to enable diagnosis and treatment through integrated products and systems that are geared to the procedures of the attending physician. Customers here are both practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers.

In the area of ophthalmic diagnostics, the company offers a range of products for investigating all clinical conditions. Examples include optical coherence tomography (OCT) devices, perimetry devices and tonometers for measuring intraocular pressure for glaucoma diagnostics. The company offers solutions for the surgical treatment of eye diseases in the area of cataract and retinal surgery, including a selection of intraocular lenses and consumables. The offering in the preoperative area for cataract treatment includes optical biometers.

In the operating room, the company supports cataract surgery with ophthalmic surgical microscopes, an OR-assistance system and phacoemulsi- fication/vitrectomy devices. The portfolio of microincision-capable intraocular lenses (IOL) extends from the standard (monofocal lenses) to the premium segment (toric multifocal lenses) and is supplemented by ophthalmic viscoelastics. The OR workstation is further completed by software-based assistance systems, such as CALLISTO eye, to assist with the implantation of toric intraocular lenses. The company intends to deliver value-added to the customer by providing interconnected systems that are precisely tailored to the surgeon's workflow. One example of this is the ZEISS Cataract Suite markerless, with which the company offers the surgeon a range of devices for cataract surgery. The product portfolio in the area of refractive surgery primarily includes systems and consumables for invasive refractive surgery.

Another focus is on networking systems and integrated data management, to make workflows in hospitals and medical practices efficient. To this end, FORUM, a data management system, offers a cross-location solution for the evaluation of clinically relevant data from various diagnostic devices and direct access to the patient's ful examination history.

Microsurgery

In the Microsurgery SBU, ZEISS provides visualization solutions for minimally invasive surgical treatments. The surgical microscopes for neurosurgery, for example, are essential tools in the surgical treatment of tumors or vascular diseases, such as aneurysms. Other areas include ear, nose and throat (ENT), plastic and reconstructive (P&R) and dental surgery, as well as spinal surgery. Add-on functions, such as video technology, three-dimensional imaging or intraoperative fluorescence options, offer the surgeon assistance in complex treatments, by delivering diagnostic data and information during the procedure in the eyepiece or on monitors. In surgical oncology, the INTRABEAM irradiation device enables the company to offer patients an intraoperative treatment option for certain types of tumor.

Strategy

The company’s strategy is to achieve sustainable, profitable growth as market and technology leader in the field of ophthalmology and microsurgery. The intention of the product range is to improve the treatment result and reduce treatment costs through efficient and effective approaches, and thus to contribute to medical progress.